Why Invest

BIOHARVEST IS THE INVENTOR OF BOTANICAL SYNTHESIS – THE PROCESS OF ISOLATING AND MAXIMIZING THE POTENCY OF PHYTO-NUTRIENTS/MEDICINAL COMPOUNDS FROM PLANTS FOR COMMERCIAL APPLICATIONS BY GROWING ONLY PLANT CELLS WITHOUT GROWING THE PLANT.

 

Chip image

Breakthrough Technology

Bring Life-changing Compounds To Commercial Markets

Beaker image

Mature Technology

Established Manufacturing Operations with Low Cost of Capita

Signature image

Expansive CDMO Opportunity

Four commercial contracts and robust deal pipeline

 

Heart pulse image

Successful D2C Health & Wellness Products Division

Recurring Revenue Subscription business
Validated Botanical Synthesis Technology

Dolar image

Attractive Operating Models For CDMO and Consumer Divisions

Provides Significant Optionality

TWO COMPLEMENTARY GROWTH ENGINES

Providing Validation For Botanical Synthesis And Strategic Optionality.

Detailed slider

     DIRECT-TO-CONSUMER PRODUCTS DIVISION     

 

VINIA®: OUR FLAGSHIP RED GRAPE CELL-DERIVED  DIRECT-TO-CONSUMER NUTRACEUTICAL PRODUCT

  • VINIA® is BioHarvest’s first commercial product. Proof of concept and market acceptance with over $70M in lifetime sales since May 2021 USA launch.

  • Breakthrough Red Grape Cell Powder that is Clinically shown to Significantly Increase Arterial Dilation, increasing blood flow and delivery of oxygen and nutrients to body’s organs, tissues and cells

  • Key Benefits: Increased Physical Energy & Mental Alertness, Healthy Blood Pressure Support, Reduces Oxidation of LDL Cholesterol, Reduces Oxidative Damage to Cells

  • Over 85,000 active customers with ~90% of online Vinia.com revenue being subscription-based, validating the demand for products created using inherent advantages of Botanical Synthesis.

  • Growing customer satisfaction (4.7/5 average rating from  10,300 + verified online reviews). Significant base of healthcare professionals using VINIA via D2D channel

  • Available in the U.S., have regulatory approval in Canada , with additional regulatory efforts underway other proprietary markets

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease

View Product Portfolio

OUR DISRUPTIVE CATEGORY PLAYBOOK ACCESSES MAJOR BILLION $ CATEGORIES

USA HEART HEALTH, ENERGY HEALTH & MENTAL ALERTNESS MARKET – $13 BN

Picture 4

USA HYDRATION MARKET – $17 BN

Stick Fruit Punch

USA FUNCTIONAL COFFEE AND TEA MARKET – $5 BN

 

 

Coming Soon

 

 

gradient separator

                      CDMO SERVICES DIVISION                      

CURRENT CDMO CONTRACTS IN TOP FOUR TARGET MARKETS

Pharma image

PHARMA & BIOTECH

HIGH MARGIN COMPOUND REPLACEMENT & NEW COMPOUND DEVELOPMENT

Nutraceuticals image

NUTRACEUTICALS

DEVELOPMENT OF COMPOUNDS TO DRIVE DIFFERENTIATION IN MAJOR COMPETITIVE PROFIT POOLS

Cosmetics image

COSMETICS & FRAGRANCES

DEVELOPMENT OF NEW HIGH MARGIN COMPOUNDS THAT WILL DRIVE INDUSTRY DIFFERENTIATION FOR MAJOR GLOBAL PLAYERS

MULTI-BILLION $
CONSUMER FUND

Nutrition image

NUTRITION & SWEETENERS

Anchored by Dec. 2024 Deal with Tate & Lyle

DEVELOPMENT OF SUPER HIGH VOLUME / LOWER MARGIN COMPOUNDS THAT WILL CHANGE THE FOOD CHAIN & FORCE BHST TO BECOME THE LOWEST COST PRODUCER OF COMPOUNDS

THE CDMO SALES FUNNEL: CURRENT CUSTOMER PROGRESS

BOTANICAL SYNTHESIS LAB-TO-CUSTOMER PROCESS IN FULL EFFECT

Customer progress chart

BHST INVESTMENT HIGHLIGHTS

Fully Funded due to successful ~$20M Q4 2025 Financing

Expanding current 20-25 tons production capacity to new capacity of ~50 tons by Q2-2027 and ~100 tons by end of 2028

D2C products division with over $32M of TTM Revenue over 85,000 active customers

Scalable CDMO platform with numerous signed customers progressing through development